Recipharm joins the AMR Industry Alliance

15 Nov 2019

Marks the latest step in the company’s ongoing efforts to engage with other organisations working to tackle antimicrobial resistance.

CDMO Recipharm is joining the AMR Industry Alliance as part of its ambition to contribute to exploring solutions to tackle growing concerns around antimicrobial resistance (AMR).

Recipharm joins the AMR Industry Alliance

The AMR Industry Alliance is one of the largest coalitions set up to provide sustainable solutions to curb AMR. With over 100 members, including biotechnology, diagnostics, generics and pharmaceutical research organisations and associations, the alliance facilitates collaboration and informs external stakeholders about new developments in the field of AMR.

Recipharm’s membership is the latest step in the company’s ongoing efforts to engage with other organisations working to tackle AMR.

Erik Haeffler, VP of Manufacturing Services and Head of Sustainability at Recipharm said, “AMR is currently one of the most serious health concerns worldwide. At Recipharm, we manufacture antibiotics in Sweden, Italy and India so it’s important that we get involved in developing solutions to combat AMR. Joining the AMR Industry Alliance was the next natural step for us to take our work on AMR to the next level and allow us to engage with other stakeholders on the subject.”

As well as joining the AMR Industry Alliance, Recipharm is also involved in a number of other initiatives focused on AMR. For example, the multisector collaboration platform, PLATINEA, led by Uppsala University designed to find ways to preserve and enhance the value of existing antibiotics and the Reducing Emissions from Antibiotic Production (REAP) project which was launched at World Water Week 2019 in Stockholm by the Stockholm International Water Institute (SIWI).

Steve Brooks, Chair of the Manufacturing Working Group at the AMR Industry Alliance said, “We welcome Recipharm as a new member of the alliance. In recent years we’ve seen more and more companies recognising and addressing AMR and we’re delighted to see a leading CDMO like Recipharm committing to the objectives of the AMR Industry Alliance, including minimizing antibiotic emissions from the manufacturing supply chain”.

AMR is recognised as a serious industry concern. The WHO, G7, G20 and many world leaders have acknowledged the growing dangers AMR presents and have called for concerted action from all relevant parties to work on solutions and their implementation.

Erik Haeffler continued, “In addition to allowing us to further explore solutions to AMR, the alliance also presents us with a framework for reducing the environmental risk of manufacturing antibiotics using risk assessments and a list of science-driven discharge concentration targets.”

“We’re confident the alliance will allow us to continue working with experts in the field of AMR and take positive steps towards developing potential solutions.”

Related news

Ajinomoto introduces fast track platform for drug product manufacturing

Ajinomoto introduces fast track platform for drug product manufacturing

30 Jun 2020

AJILITY is designed to speed novel or existing therapeutics from development to manufacturing and into the clinic.

Read more 
Piramal acquires solid oral dosage drug product facility from G&W Laboratories

Piramal acquires solid oral dosage drug product facility from G&W Laboratories

22 Jun 2020

The site can also produce liquids, creams, and ointments, further expanding the CDMO's portfolio.

Read more 
Catalent and ViralClear Pharmaceuticals partner on potential COVID-19 treatment

Catalent and ViralClear Pharmaceuticals partner on potential COVID-19 treatment

22 Jun 2020

The CDMO will work on developing a solution and a solid oral dosage form of ViralClear's merimepodib.

Read more 
Sanofi to build EUR 490 million vaccine production facility in France

Sanofi to build EUR 490 million vaccine production facility in France

16 Jun 2020

The French pharma company will also invest EUR 120 million to create a new research center at Marcy-l'Etoile dedicated to vaccines

Read more 
Vektor Pharma finalizes formula for novel transdermal drug delivery system to treat Parkinson's

Vektor Pharma finalizes formula for novel transdermal drug delivery system to treat Parkinson's

8 Jun 2020

Optimizing the dosage form's efficiency reduces the amount of drug required in each patch.

Read more 
Emergent bags $628 million landmark CDMO deal to produce COVID-19 vaccine candidates

Emergent bags $628 million "landmark" CDMO deal to produce COVID-19 vaccine candidates

2 Jun 2020

The company will provide CDMO capabilities, capacities, and expertise to support the US government’s Warp Speed Program to pave the way for innovators to advance COVID-19 programs.

Read more 
Changes needed to prevent controversial pay-for-delay pharma deals

Changes needed to prevent controversial pay-for-delay pharma deals

26 May 2020

Researchers endorse a switch from the current first-filer system in the US to a system that instead rewards the first successful challenger.

Read more 
SeraNova and Carna Biosciences to develop oral formulation of a new active ingredient

SeraNova and Carna Biosciences to develop oral formulation of a new active ingredient

26 May 2020

SeraNovo enters into a second license agreement with Carna Biosciences for development of oral formulation of Carna’s kinase inhibitor.

Read more 
AbCellera and Lilly seal multi-year antibody discovery collaboration

AbCellera and Lilly seal multi-year antibody discovery collaboration

25 May 2020

AbCellera, will use its antibody drug discovery platform to identify antibodies against up to nine targets.

Read more 
HKBU invents nanostructure that stimulates growth of stem cells for Parkinson's treatment

HKBU invents nanostructure that stimulates growth of stem cells for Parkinson's treatment

25 May 2020

The invention could pave the way for treatments to cure Parkinson's and Alzheimer's disease.

Read more